AChE inhibitors address one of the core deficits universally observed in AD, the extensive loss of the basal forebrain cholinergic system and a loss of CNS cholinergic tone that is associated with cognitive loss, suffering and severe medicoeconomic costs. This evidence concerns the gene ACHE and Alzheimer disease.